GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Quantrx Biomedical Corp (OTCPK:QTXB) » Definitions » Enterprise Value

Quantrx Biomedical (Quantrx Biomedical) Enterprise Value : $3.20 Mil (As of May. 22, 2024)


View and export this data going back to . Start your Free Trial

What is Quantrx Biomedical Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Quantrx Biomedical's Enterprise Value is $3.20 Mil. Quantrx Biomedical's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.05 Mil. Therefore, Quantrx Biomedical's EV-to-EBIT ratio for today is -71.16.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Quantrx Biomedical's Enterprise Value is $3.20 Mil. Quantrx Biomedical's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.05 Mil. Therefore, Quantrx Biomedical's EV-to-EBITDA ratio for today is -71.16.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Quantrx Biomedical's Enterprise Value is $3.20 Mil. Quantrx Biomedical's Revenue for the trailing twelve months (TTM) ended in Sep. 2022 was $0.00 Mil. Therefore, Quantrx Biomedical's EV-to-Revenue ratio for today is .


Quantrx Biomedical Enterprise Value Historical Data

The historical data trend for Quantrx Biomedical's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantrx Biomedical Enterprise Value Chart

Quantrx Biomedical Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.44 2.53 2.92 2.90 3.48

Quantrx Biomedical Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.71 3.48 3.21 3.24 3.34

Competitive Comparison of Quantrx Biomedical's Enterprise Value

For the Medical Instruments & Supplies subindustry, Quantrx Biomedical's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quantrx Biomedical's Enterprise Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Quantrx Biomedical's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Quantrx Biomedical's Enterprise Value falls into.



Quantrx Biomedical Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Quantrx Biomedical's Enterprise Value for the fiscal year that ended in Dec. 2021 is calculated as

Quantrx Biomedical's Enterprise Value for the quarter that ended in Sep. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quantrx Biomedical  (OTCPK:QTXB) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Quantrx Biomedical's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=3.202/-0.045
=-71.16

Quantrx Biomedical's current Enterprise Value is $3.20 Mil.
Quantrx Biomedical's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.05 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Quantrx Biomedical's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=3.202/-0.045
=-71.16

Quantrx Biomedical's current Enterprise Value is $3.20 Mil.
Quantrx Biomedical's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.05 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Quantrx Biomedical's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=3.202/0
=

Quantrx Biomedical's current Enterprise Value is $3.20 Mil.
Quantrx Biomedical's Revenue for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quantrx Biomedical Enterprise Value Related Terms

Thank you for viewing the detailed overview of Quantrx Biomedical's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Quantrx Biomedical (Quantrx Biomedical) Business Description

Traded in Other Exchanges
N/A
Address
10190 SW 90th Avenue, Tualatin, OR, USA, 97062
Quantrx Biomedical Corp operates towards the development and commercialization of patented mini form pad (PAD) based products. The PAD products are based on the company's non-woven disposable absorbent pad technology and it is involved in the PAD-based over-the-counter products for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs. Its platforms include inSync(R), Unique(TM), and OEM branded over-the-counter and laboratory testing products.
Executives
Michael S Abrams director 64 RAMSHEAD ROAD, RAYNHAM MA 02767
Patrick T Mooney director C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
Robert G. Pinco director 1700 K STREET NW, SUITE 300, WASHINGTON DC 20006
Hayes Arthur H Jr director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Matthew Balk 10 percent owner 229 WEST 60TH STREET, NEW YORK NY 10023
Evan Levine director, 10 percent owner 1517 SAN JACINTO ST., HOUSTON TX 77002
Hayes Arthur Hull Jr director C/O QUANTRX BIOMEDICAL CORPORATION, 100 S. MAIN STREET, SUITE 300, DOYLESTOWN PA 18901
Cindy Horton officer: V.P. of Diagnostics 209 BRITTANY PARK, ANDERSON SC 29621
Sasha Afanassiev officer: Officer 120 GARRISON COURT, LANGHORNE PA 19047
Shalom Hirschman officer: Officer 5240 BLACKSTONE AVENUE, RIVERDALE NY 10471
William H Fleming director, officer: Secretary
Walter W Witoshkin director, officer: President and CEO 321 NORRISTOWN ROAD, SUITE 230, AMBLE PA 19002
Mark Capital Llc 10 percent owner 5173 SEAGROVE PLACE, SAN DIEGO CA 92130
Sherbrooke Partners, Llc 10 percent owner 570 LEXINGTON AVENUE, FLOOR 3, NEW YORK NY 10022
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282

Quantrx Biomedical (Quantrx Biomedical) Headlines

No Headlines